AIMOVIG (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
AIMOVIG
Date registered
Evaluation commenced
Decision date
Approval time
178 working days (255)
Active ingredients
erenumab (rch)
Registration type
NCE/NBE
Indication
AIMOVIG (solution for injection) is indicated for prophylaxis of migraine in adults.